Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 39 |
| Active Pipeline (Recruiting Now) | 14 (9) |
| Completed vs Stopped Early | 10 / 0 (0.0%) |
| Median Closed Actual Enrollment | 142 participants |
| Physical Hospital Site Disclosure | 79.3% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Shanghai General Hospital | Shanghai | 4 |
| Peking University People's Hospital | Beijing, Beijing Municipality | 3 |
| Shenzhen People's Hospital | Shenzhen, Guangdong | 2 |
Explore interactive annual charts and M&A subsidiary rollups in the Sunshine Guojian Pharmaceutical (Shanghai) Co Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.